Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.00%
)
US TECH 100
28,315.80
(
-1.65%
)
Dow Jones
50,063.46
(
0.00%
)
Brent Oil
105.40
(
1.17%
)
Bitcoin
80,126.66
(
-1.13%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 160950

Friday, 06/28/2013 10:29:20 AM

Friday, June 28, 2013 10:29:20 AM

Post# of 257566
EU approves first mAb biosimilars: HSP’s and Celltrion’s knockoffs of JNJ/MRK’s Remicade, which are called Remsima and Inflectra, respectively:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1

MRK has the commercial rights to Remicade in the EU, where it is patent-protected in some countries until 2014.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today